The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab plus FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study.
 
Eric Chen
Honoraria - AstraZeneca Canada; Eisai; GlaxoSmithKline; Merck; Pfizer; Roche; Takeda
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Repare Therapeutics; Roche Canada
 
Rozita Abdul Malik
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Malaysia) Sdn Bhd (Inst); Novartis (Inst); Roche (Malaysia) Sdn Bhd (Inst)
 
Harvey Yu-Li Su
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Fresenius Kabi; Johnson & Johnson/Janssen; Merck KGaA; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Merck Serono; MSD Oncology
Speakers' Bureau - Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Takeda
 
Pei Jye Voon
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Johnson & Johnson/Janssen; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Amgen; AstraZeneca; Johnson & Johnson/Janssen; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Johnson & Johnson/Janssen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Revolution Medicines (Inst); ROCHE (Inst); Viracta Therapeutics (Inst)
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Dirk Arnold
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol Myers Squibb Foundation; CRA International; Gilead Sciences; Janssen-Cilag; Merck Sharp & Dohme; Onkowissen; Pierre Fabre; Seagen; Takeda; TERUMO
Research Funding - Abbvie (Inst)
Other Relationship - Amgen; Aptitude Health; art tempi media; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Clinical Care Options; Eisai; Elsevier; From Research to Practice; GlaxoSmithKline; Imedex; IOMEDICO (Germany); Ipsen; Merck (Serono); Miami Cancer Institute; PeerMD (China); PRMA Consulting; Sanofi (Genzyme); Sanofi (Genzyme) (Inst); SERVIER; Sirtex Medical; streamitup Germany; Tactics MD LLC; Viatris; WebMD Health Corp
(OPTIONAL) Uncompensated Relationships - AIO (German Cancer Society); European Organisation for Research and Treatment of Cancer (EORTC); Oncolytics (Inst); Phanes Therapeutics Inc
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; ALX Oncology; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Civala; Fog Pharmaceuticals; MBQ Pharma; Merus NV; Revolution Medicines; Urogen pharma; Urogen pharma; Xilio Therapeutics; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Ying Yuan
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Pilar Garcia-Alfonso
Honoraria - Amgen, Merck, MSD, BMS, Servier, Takeda, Piere Fabre
Consulting or Advisory Role - Amgen, BMS, Servier, Piere Fabre
Travel, Accommodations, Expenses - Amgen, Merck, MSD, BMS, Servier, Takeda, Piere Fabre
 
Sreenivasa Chandana
Leadership - The Cancer & Hematology Centers
Consulting or Advisory Role - AstraZeneca; IPSEN
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Seung-Hoon Beom
No Relationships to Disclose
 
Sanjib Chowdhury
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Xuesong Lu
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Rianka Bhattacharya
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Mahesh Daksh
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Cecilia Monge
No Relationships to Disclose
 
Seema Sethi
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation